A circulating biomarker for use in monitoring metastatic breast cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA210817
- Recipient
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,368,496
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Funding
-
- $1,226,836.16 Federal
- $141,660.00 Non-federal
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | -$99,823 | $0 | |
| Amendment | -$99,823 | $0 | |
| Amendment | -$99,823 | $0 | |
| Amendment | $70,818 | $0 | |
| Amendment | $70,818 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $141,660 | $0 | |
| Amendment | $141,660 | $141,660 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $1,101,350 | $0 |
Show all 17
Quick answers
Who received award R44CA210817?
R44CA210817 was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on March 15, 2017.
How much is award R44CA210817 worth?
$1,368,496 has been obligated on R44CA210817: $1,226,836 in federal funding and $141,660 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award